GlassScriptPhysician profile
Farjam Farzam
NPI 1497850556
$978.84
in general payments reported to CMS, 2019-2025
19 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.97 · 2020: $24.30 · 2021: $64.97 · 2022: $163 · 2023: $199 · 2024: $233 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $250.04 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $105.52 | 2021-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $92.35 | 2023-2024 | |
| Harmony Biosciences LLC | $49.69 | 2025 | |
| Ironshore Pharmaceuticals INC. | $43.32 | 2019-2024 | |
| Genentech USA, INC. | $42.46 | 2024 | Evrysdi |
| Boston Scientific Corporation | $40.60 | 2022 | |
| Aquestive Therapeutics, INC. | $40.19 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $38.98 | 2019 | |
| Livanova USA, INC. | $35.88 | 2019-2021 | |
| Sk Life Science, INC. | $33.59 | 2023 | |
| Supernus Pharmaceuticals, INC. | $31.05 | 2022 | |
| Aucta Pharmaceuticals, INC. | $29.97 | 2024-2025 | Motpoly Xr |
| Biocodex, INC. | $25.65 | 2023 | Diacomit |
| Springworks Therapeutics, INC. | $24.54 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $24.30 | 2020 | |
| Corium, LLC | $24.21 | 2022 | |
| Acadia Pharmaceuticals INC | $23.54 | 2023 | Daybue |
| Tris Pharma INC | $22.96 | 2025 | Onyda Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farjam Farzam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.